ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Tvardi Therapeutics (TVRD)
Tvardi Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.84▼ -10.43%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Tvardi Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Tvardi Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Tvardi Therapeutics a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.69 and $0.96; in 9 out of 10, between $0.51 and $1.29. Estimated annual volatility is 102%.
Price, last 12 months (weekly close)
Key numbers
- 52-week high
- $5.69
- 52-week low
- $0.84
- Revenue (12 months)
- $0.0M
- Return on equity
- -126.2%
- Free cash flow (12 months)
- $-16.3M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for TVRD right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks TVRD has traded between $0.84 and $5.69. Today it is 85.2% below that high and 0% above its low.
Its beta is 0.00: it tends to move less than the market.
About the company
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies that target STAT3, a signaling pathway associated with inflammatory and proliferative diseases.
Want to see everything about Tvardi Therapeutics?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does Tvardi Therapeutics do?
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies that target STAT3, a signaling pathway associated with inflammatory and proliferative diseases.
What is the chance TVRD goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, TVRD ends the month between $0.69 and $0.96.
How volatile is TVRD?
ATLAS estimates annual volatility at 102%. In a typical month, half of the outcomes end between $0.69 and $0.96.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer